HCP check
HCP check

Welcome to SHPT Challenges

This website contains information about secondary hyperparathyroidism (SHPT). It is intended to provide information to an international audience outside of the USA.

You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?

Confirm

Cancel

According to RCTs,

nutritional vitamin D is

ineffective at consistently

reducing PTH and often

delays effective therapy.1,15

 

In contrast, active vitamin D

and active analogues can

reduce PTH, but they:

  • Do not correct 25(OH)D1
  • Increase the risks of hypercalcaemia and hyperphosphataemia1,16–18
/sites/g/files/brlbcj1106/files/2020-03/Background_Bricks_1400-min-min-min.png

LIMITATIONS OF NUTRITIONAL VITAMIN D,
ACTIVE VITAMIN D AND ITS ANALOGUES

/sites/g/files/brlbcj1106/files/2020-06/Effects_on_CKD_2-min.png

25(OH)D: 25-hydroxyvitamin D; CKD–MBD: chronic kidney disease–mineral and bone disorder; FGF-23: fibroblast growth factor-23; PTH: parathyroid hormone; RCT: randomised controlled trial.